Brief: NCC, PeptiDream Announce First Dosing of 64Cu-PD-32766 In Patient with Clear Cell Renal Cell Carcinoma
04/06/2024 12:57
June 4 (Reuters) - NCC and PeptiDream:
* NCC AND PEPTIDREAM ANNOUNCE THE FIRST DOSING OF
64CU-PD-32766 IN
A PATIENT WITH CLEAR CELL RENAL CELL CARCINOMA
Source text for Eikon: ID:nBw4GKQwGa
((Reuters.Briefs@thomsonreuters.com;))
Recent news on PeptiDream
See all newsTable: Peptidream 6-MTH group results (IFRS)
Brief: Peptidream Inc. - Initiation Of Phase 1 Clinical Trial By Novartis Marks Milestone For Peptidream
Brief: PeptiDream Announces First Dosing Of 64cu-Pd-29,875 In Gastric Cancer Patients
Table: Peptidream -Q1 group results (IFRS)
Brief: Peptidream Announces The Initiation Of Phase 1 Clinical Trial By Its Collaboration Partner